Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA approval
Pharma
FDA signs off on UroGen's Zusduri after advisory committee snub
Zusduri is the first approved therapy for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.
Zoey Becker
Jun 13, 2025 8:56am
With lung cancer FDA nod, it's David versus Goliath
Jun 11, 2025 4:17pm
FDA signs off on Enflonsia, Merck's RSV shot for infants
Jun 9, 2025 4:33pm
FDA approves use of Bayer's Nubeqa in all patients with mCSPC
Jun 4, 2025 11:38am
Alcon gains first FDA prescription drug nod since Novartis split
May 29, 2025 10:20am
GSK revs up launch plans after Nucala's FDA approval in COPD
May 22, 2025 3:10pm
